Health Risks Associated with Peptide Use

Introduction

As of October 2026, most peptides bodybuilders use are sold as "research use only," with no drug label or tested human dose. FDA's 2026 warning letters say that label doesn't protect sellers; see our overview of peptide legal status. Our main article on peptide health risks covers each peptide class.

Hormonal Disruption

Growth Hormone Axis Effects

Effect	Mechanism	Reversibility
Smaller GH response	Desensitization	Partial, reversible (hexarelin)
IGF-1 elevation	Downstream effect	Dose-dependent
Insulin resistance	Metabolic adaptation	Seen with MK-677; not measured
Thyroid effects	Hormonal crosstalk	Not studied

Reproductive Hormones

Effect	Mechanism	Concern Level
Testosterone changes	Indirect effects	Unclear
Fertility impacts	Hormonal disruption	Unknown long-term
Menstrual changes	Endocrine effects	User reports only

Cardiovascular Risks

Documented Effects

Risk	Mechanism	Evidence Level
Cardiomegaly	Chronic GH excess	Acromegaly data only
Fluid retention	Sodium retention	Mild edema in MK-677 trial
Heart rate changes	Vasodilation	FDA cites CJC-1295 reports
Heart failure	Unclear	MK-677 trial stopped early
Lipid alterations	Metabolic effects	Variable

Monitoring Recommendations

Checks users commonly arrange:

Regular blood pressure checks
Cardiac imaging if symptomatic
Lipid panel monitoring
ECG if concerns arise

Metabolic Effects

Blood Sugar

Effect	Mechanism	Evidence
Insulin resistance	GH opposition	Glucose up about 5 mg/dL (MK-677)
Hypoglycemia risk	IGF-1 effects	On mecasermin label
Diabetes acceleration	Chronic use	Pre-existing risk factor

Other Metabolic Concerns

Users sometimes blame these on vial impurities (untested):

Electrolyte imbalances
Liver enzyme elevations

Psychological Effects

Reported Issues

Effect	Frequency	Notes
Mood changes	User reports	Unmeasured
Anxiety	User reports	Individual variation
Sleep disturbance	User reports	Unmeasured
Body dysmorphia	Risk factor	Linked to steroid abuse (1997 paper)

Cancer Considerations

Theoretical Concerns

Factor	Consideration	Evidence
IGF-1 and cancer	Growth promotion	Modest link (2004 meta-analysis)
GH and malignancy	Proliferative effects	Colon polyps in acromegaly
Long-term risk	Unknown	Insufficient data

Perspective

No direct causation shown in peptide users
Active cancer is a contraindication on the mecasermin label

Unknown Risks

Areas of Uncertainty

Area	Concern	Status
Novel peptides	Unknown safety profile	No human data
Vial contents	Purity and dose	41.6-71.1% failed testing (2026 preprint)
Long-term use	Decade+ effects	Not studied
Drug interactions	Unpredictable	Not studied
Individual variation	Genetic factors	Poorly understood

Risk Mitigation

Users commonly describe these steps, but none has been tested in a trial. Our sourcing and quality control guide covers lab reports.

Strategies

Strategy	Benefit
Medical supervision	Early detection
Regular blood work	Monitoring markers
Cycling protocols	Receptor recovery (partial evidence)
Quality sourcing	Fewer contaminants
Symptom awareness	Prompt intervention

What to Watch Next

In July 2026, an FDA advisory committee backed compounding BPC-157 and TB-500, among others. As of October 2026, FDA hasn't finished the rulemaking. Even a final rule wouldn't settle the long-term health risks.